Advaxis, Inc.
Companies
1993-2019
Filing Dates

555 filings

Newest first
8-K
ADXS Advaxis, Inc.
13 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8-K
ADXS Advaxis, Inc.
9 Sep 19
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
10-Q
2019 Q3
ADXS Advaxis, Inc.
9 Sep 19
Quarterly report
8-K
ADXS Advaxis, Inc.
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8-K
ADXS Advaxis, Inc.
22 Aug 19
Advaxis, Inc. Issues Letter to Shareholders
8-K
ADXS Advaxis, Inc.
31 Jul 19
Material Modifications to Rights of Security Holders
8-K
ADXS Advaxis, Inc.
25 Jul 19
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
424B4
ADXS Advaxis, Inc.
24 Jul 19
Prospectus supplement with pricing info
EFFECT
ADXS Advaxis, Inc.
23 Jul 19
Notice of effectiveness
S-1/A
ADXS Advaxis, Inc.
22 Jul 19
IPO registration (amended)
CORRESP
ADXS Advaxis, Inc.
18 Jul 19
Correspondence with SEC
CORRESP
ADXS Advaxis, Inc.
18 Jul 19
Correspondence with SEC
FWP
ADXS Advaxis, Inc.
17 Jul 19
Free writing prospectus
S-1/A
ADXS Advaxis, Inc.
17 Jul 19
IPO registration (amended)
8-K
ADXS Advaxis, Inc.
15 Jul 19
Other Events
UPLOAD
ADXS Advaxis, Inc.
9 Jul 19
Letter from SEC
S-1
ADXS Advaxis, Inc.
2 Jul 19
IPO registration
8-K
ADXS Advaxis, Inc.
27 Jun 19
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of its Phase 3 AIM2CERV Study
8-K
ADXS Advaxis, Inc.
10 Jun 19
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
10-Q
2019 Q2
ADXS Advaxis, Inc.
10 Jun 19
Quarterly report